CERENOME, INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
CNSY$0.57-11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
EXHIBIT INDEX
| ExhibitNumber | Exhibit Title | Filed withthis Form10-K | Incorporated by Reference | ||
| Form | File No. | Date Filed | |||
| 3.1 | Composite Certificate of Incorporation | 10-K | 001-34375Exhibit 3.1 | 03/11/2016 | |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation | 8-K | 001-34375Exhibit 3.1 | 05/10/2016 | |
| 3.3 | Certificate of Amendment to Amended and Restated Certificate of Incorporation | 8-K | 001-34375Exhibit 3.1 | 05/23/2018 | |
| 3.4 | Certificate of Amendment to Amended and Restated Certificate of Incorporation | 8-K | 001-34375Exhibit 3.1 | 07/29/2019 | |
| 3.5 | Certificate of Amendment to Amended and Restated Certificate of Incorporation | 8-K | 001-34375Exhibit 3.1 | 08/06/2019 | |
| 3.6 | Certificate of Amendment to Amended and Restated Certificate of Incorporation | 8-K | 001-34375Exhibit 3.1 | 4/28/2023 | |
| 3.7 | Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock | 8-K | 001-34375Exhibit 3.1 | 11/28/2017 | |
| 3.8 | Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock | 8-K | 001-34375Exhibit 3.1 | 07/25/2018 | |
| 3.9 | Amended and Restated Bylaws of Plus Therapeutics, Inc. | 8-K | 001-34375Exhibit 3.1 | 09/21/2021 | |
| 4.1 | Description of Securities | 10-K | 001-34375Exhibit 4.1 | 03/30/2020 | |
| 4.2 | Form of Common Stock Certificate | 10-K | 001-34375Exhibit 4.33 | 03/09/2018 | |
| 4.3 | Form of Warrant Amendment Agreement | 8-K | 011-34375Exhibit 4.1 | 04/23/2020 | |
| 4.4 | Form of Underwriters’ Warrant Amendment Agreement | 8-K | 011-34375Exhibit 4.1 | 10/05/2020 | |
| 4.5 | Form of Pre-Funded Warrant | 8-K | 011-34375Exhibit 4.1 | 05/09/2024 | |
| 4.6 | Form of Series A Warrant (May 2024, as amended and restated August 2024) | 10-Q | 011-34375Exhibit 4.5 | 08/14/2024 | |
| 4.7 | Form of Series B Warrant (May 2024, as amended and restated August 2024) | 10-Q | 011-34375Exhibit 4.6 | 08/14/2024 | |
| 4.8 | Form of Amendment and Restatement of the Plus Therapeutics, Inc. Series A Common Stock Purchase Warrant | 10-Q | 011-34375Exhibit 4.7 | 08/14/2024 | |
| 4.9 | Form of Amendment and Restatement of the Plus Therapeutics, Inc. Series B Common Stock Purchase Warrant | 10-Q | 011-34375Exhibit 4.8 | 08/14/2024 | |
| 4.10 | Form of Pre-Funded Warrant | 8-K | 011-34375Exhibit 4.1 | 02/18/2025 | |
| 4.11 | Form of Warrant issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 011-34375Exhibit 4.2 | 02/18/2025 | |
| 4.12 | Form of Pre-Funded Warrant | 8-K | 011-34375Exhibit 4.1 | 03/04/2025 | |
| 4.13 | Form of Series A Warrant | 8-K | 011-34375Exhibit 4.2 | 03/04/2025 | |
| 4.14 | Form of Series B Warrant | 8-K | 011-34375Exhibit 4.3 | 03/04/2025 | |
| 10.1+ | Patent and Know-How License Agreement, dated March 29, 2020, by and between Plus Therapeutics, Inc. and NanoTx, Corp. | 8-K | 011-34375 Exhibit 10.1 | 3/30/2020 |
| 10.2+ | Patent & Technology License Agreement, dated December 31, 2021, by and between Plus Therapeutics, Inc. and the University of Texas Health Science Center at San Antonio | 10-K | 011-34375 Exhibit 10.2 | 2/24/2022 |
| 10.3 | Purchase Agreement, dated August 2, 2022, by and between Lincoln Park Capital Fund, LLC and Plus Therapeutics, Inc. | 8-K | 011-34375 Exhibit 10.1 | 08/08/2022 |
| 10.4 | Registration Rights Agreement, dated August 2, 2022, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund | 8-K | 001-34375Exhibit 10.6 | 08/08/2022 |
| 10.5# | Amended and Restated Employment Agreement, dated March 11, 2020, by and between Marc Hedrick and Plus Therapeutics, Inc. | 10-Q | 001-34375Exhibit 10.6 | 5/14/2020 |
| 10.6# | Amended and Restated Employment Agreement, dated March 11, 2020, by and between Andrew Sims and Plus Therapeutics, Inc. | 10-Q | 001-34375Exhibit 10.7 | 5/14/2020 |
| 10.7# | 2015 New Employee Incentive Plan | 8-K | 001-34375Exhibit 10.1 | 01/05/2016 |
| 10.8# | First Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated January 26, 2017 | 10-K | 001-34375Exhibit 10.42 | 03/24/2017 |
| 10.9# | Second Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated February 6, 2020 | 10-K | 001-34375 Exhibit 10.25 | 03/30/2020 |
| 10.10# | Third Amendment to the 2015 New Employee Incentive Plan | S-1 | 333-280061Exhibit 10.15 | 06/07/2024 |
| 10.11# | Form of Notice of Grant of Stock Option under the 2015 New Employee Incentive Plan | S-8 | 333-210211Exhibit 99.5 | 03/15/2016 |
| 10.12# | Form of Stock Option Agreement under the 2015 New Employee Incentive Plan | S-8 | 333-210211Exhibit 99.4 | 03/15/2016 |
| 10.13# | Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as amended and restated | 8-K | 001-34375Exhibit 10.1 | 05/20/2021 |
| 10.14# | Form of Notice of Grant and Stock Option Agreement under the 2020 Stock Incentive Plan | 10-K | 001-34375Exhibit 10.26 | 02/24/2022 |
| 10.15# | Form of Indemnification Agreement | 8-K | 001-34375Exhibit 10.1 | 02/06/2020 |
| 10.16# | Form of Agreement for Acceleration and/or Severance | 10-K | 001-34375Exhibit 10.113 | 03/11/2016 |
| 10.17 | Medidata Services Agreement and Statement of Work, dated November 5, 2021, by and between Medidata Solutions, Inc. and Plus Therapeutics, Inc. | 10-Q | 001-34375Exhibit 10.1 | 04/21/2022 |
| 10.18+ | Cancer Research Grant Contract, effective August 31, 2022, by and between the Cancer Prevention and Research Institute of Texas and Plus Therapeutics, Inc. | 8-K | 001-34375Exhibit 10.1 | 09/22/2022 |
| 10.19 | Subscription and Investment Representation Agreement, dated March 3, 2023, by and between Plus Therapeutics, Inc. and the purchaser signatory thereto | 8-K | 001-34375Exhibit 10.1 | 03/03/2023 |
| 10.20# | Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as further amended and restated | 8-K | 001-34375Exhibit 10.1 | 04/20/2023 |
| 10.21 | Securities Purchase Agreement, dated as of May 5, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.1 | 05/09/2024 |
| 10.22 | First Amendment to Securities Purchase Agreement, dated as of May 8, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.2 | 05/09/2024 |
| 10.23 | Registration Rights Agreement, dated as of May 5, 2024, by and among Plus Therapeutics, Inc., and the purchases named therein | 8-K | 001-34375Exhibit 10.3 | 05/09/2024 | |
| 10.24 | Lending Agreement, dated April 5, 2024, by and between Plus Therapeutics, Inc and Pershing LLC | 8-K | 001-34375Exhibit 10.1 | 06/04/2024 | |
| 10.25 | Loan Interest Rate Form, dated May 24, 2024, by and between Plus Therapeutics, Inc and Pershing LLC | 8-K | 001-34375Exhibit 10.2 | 06/04/2024 | |
| 10.26 | Extension of Credit, dated May 29, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC | 8-K | 001-34375Exhibit 10.3 | 06/04/2024 | |
| 10.27* | Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.1 | 02/18/2025 | |
| 10.28 | Form of Secured Convertible Note for Funding Notes issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers names therein | 8-K | 001-34375Exhibit 10.2 | 02/18/2025 | |
| 10.29 | Form of Secured Convertible Note for Exchange Notes issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers names therein | 8-K | 001-34375Exhibit 10.3 | 02/18/2025 | |
| 10.30* | Security Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc., CNSide Diagnostics, LLC and Iroqouis Master Fund Ltd., as collateral agent for the purchasers names therein | 8-K | 001-34375Exhibit 10.4 | 02/18/2025 | |
| 10.31 | Subsidiary Guarantee, dated as of February 13, 2025, by and among CNSide Diagnostics, LLC and the purchasers named therein | 8-K | 001-34375Exhibit 10.5 | 02/18/2025 | |
| 10.32 | Registration Rights Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.6 | 02/18/2025 | |
| 10.33 | Second Amendment to Securities Purchase Agreement, dated May 5, 2024, as amended on May 9, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.7 | 02/18/2025 | |
| 10.34 | Securities Purchase Agreement, dated as of March 4, 2025 | 8-K | 001-34375Exhibit 10.1 | 03/04/2025 | |
| 10.35 | Registration Rights Agreement, dated as of March 4, 2025 | 8-K | 001-34375Exhibit 10.2 | 03/04/2025 | |
| 10.36 | First Amendment to Securities Purchase and Exchange Agreement, dated as of March 4, 2025 | 8-K | 001-34375Exhibit 10.3 | 03/04/2025 | |
| 19 | Insider Trading Policy | X | |||
| 21 | List of Subsidiaries | X | |||
| 23.1 | Consent of BDO USA, P.C., Independent Registered Public Accounting Firm | X | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 31.2 | Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32.1† | Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes -Oxley Act of 2002 | X | |||
| 97.1 | Incentive Compensation Recovery Policy | 10-K | 001-34375Exhibit 97.1 | 03/05/2024 | |
| 101.INS | The following financial information from The Plus Therapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Balance Sheets as of December 31, 2024 and 2023; (ii) Statements of Operations for the years ended December 31, 2024 and 2023; (iii) Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023; (iv) Statements of Cash Flows for the years ended December 31, 2024 and 2023; and (v) Notes to Financial Statements. | X | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | X | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.